

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

-----X  
In re Application of: :  
Bahige M. Baroudy et al :  
: Examiner: To be assigned  
For Patent For: :  
Piperazine Derivatives Useful as :  
CCR5 Antagonists :  
: Art Unit: To be assigned  
Serial No.: To be assigned :  
Filing Date: To be assigned :  
-----X

Schering-Plough Corporation  
Kenilworth, New Jersey 07033-0530

Commissioner for Patents  
PO Box 1450  
Alexandria VA 2231301450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

This statement is made in compliance with 37 C.F.R. 1.56, 1.97 and 1.98. Applicants enclose a Form PTO-1449 (one page) listing publications known to applicants that may be relevant to this application. This Statement accompanies the filing of this divisional application.

Publications AA-AD, AL, AM and AR-AZ were cited in the specification. AA-AC disclose piperazinyl muscarinic antagonists; AD relates to IL-10; AR discusses various treatments of HIV-1; AS discloses an HIV-1 assay; AT-AY disclose various studies of CCR5 receptor activity; and AZ discloses the preparation of an intermediate. (Applicants note that the citation listed on the 1449 form is the correct citation; the specification on page 35 erroneously refers to a JACS article, when it should have been JOC). AL is equivalent to AA, and AM claims subject matter related to AC.

AN and AO were cited in a co-owned application claiming related subject matter (09,305,226, abandoned). AP and AQ were cited in the International Search Report of corresponding International Application WO 00/66558; AM was also cited in the Search Report. AE was cited by the examiner in the grandparent application; BR, BS and BT were cited by applicants in the grandparent application in support of the anti-HIV utility.

Copies of the references are not provided since they should be available in the file of the parent and/or grandparent application. If copies are needed, please notify the undersigned.

Applicants note that about twenty additional references are listed on pages 10-13 of the specification as disclosing the various other agents to be used in combination with the presently claimed compounds. It is urged that these references relate to those other agents and do not need to be cited in this application. If, however, the examiner would like copies of those references, applicants will supply them upon request.

The examiner is requested to examine the publications, to initial the form PTO-1449 and to return a copy of the initialed form to applicants.

Respectfully submitted,

9/23/03

Date



Anita W. Magatti  
Reg. No. 29,825  
Attorney for Applicants  
(908) 298-5067

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: IN01032K1C		SERIAL NO.: To Be Assigned	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>				APPLICANT: Bahige M. Baroudy, et al.			
				FILING DATE: To Be Assigned		GROUP: To Be Assigned	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	5,883,096	3/16/99	Lowe et al	514		
	AB	6,037,352	3/14/00	Lowe et al	514		
	AC	5,889,006	3/30/99	Lowe et al	519		
	AD	5,368,854	11/29/94	Rennick	424		
	AE	6,066,636	5/23/00	Kozlowski et al	514		
	AF						
	AG						
	AH						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL	WO 96/26196	8/29/96	WIPO			
	AM	WO 98/05292	2/12/98	WIPO			
	AN	WO 97/16440	5/9/97	WIPO			
	AO	WO 94/18192	8/18/94	WIPO			
	AP	WO 00/00488	1/6/00	WIPO			
	AQ	WO 99/04794	2/4/99	WIPO			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	AR	Vandamme et al, <u>Antiviral Chemistry and Chemotherapy</u> , <u>9</u> (1998) p. 187-203					
	AS	Connor et al, <u>Virology</u> , <u>206</u> (1995) p. 935-944					
	AT	Plater-Zyberk et al, <u>Immunol. Let.</u> , <u>57</u> (1997) p. 117-120					
	AU	Boiardi et al, <u>Clinical and Experimental Rheumatology</u> , <u>17</u> , (1999) p. 419-425					
	AV	Hatano et al, <u>Clin. Exp. Immunol.</u> , <u>117</u> (1999) p. 237-243					
	AW	Raychaudhuri et al, <u>International J. of Immunopharmacology</u> , <u>20</u> (1998) p. 661-667					
	AX	Chihara et al, <u>J. Allergy Clin. Immunol.</u> , <u>100</u> , 6, part 2 (1997) p. S52-S55					
	AY	Beck et al, <u>J. Immunol.</u> , <u>159</u> , 6 (1997) p. 2962-72					
	AZ	Thea et al, <u>J. Org. Chem.</u> , <u>50</u> (1985) p. 1867-1872					
	BR	Deng et al, <u>Nature</u> , <u>381</u> (1996) p. 661-666					
	BS	Dragic et al, <u>Nature</u> , <u>381</u> (1996) p. 667-673					
	BT	Liu et al, <u>Cell</u> , <u>86</u> (1996) p. 367-377					
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							